KIM
ALNY icon

Kestra Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kestra Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$788K Sell
2,618
-5,778
-69% -$1.74M 0.02% 264
2026
Q1 		$2.78M Buy
8,396
+2,382
+40% +$811K 0.05% 101
2025
Q4 		$2.39M Buy
+6,014
New +$2.66M 0.06% 120
2025
Q1 		– Sell
-3
Closed -$706 – 914
2024
Q4 		$706 Buy
+3
New +$789 ﹤0.01% 1116

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kestra Investment Management's ALNY Position: Q2 2026 in Review

Kestra Investment Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 69% in Q2 2026, selling an estimated $1.74M and leaving 2,618 shares worth $788K. The position accounts for 0.02% of the portfolio, ranked #264.

Kestra Investment Management first reported a position in ALNY in Q4 2024 and has held it in 4 quarters since. The position peaked at $2.78M in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Kestra Investment Management held 2,618 shares of Alnylam Pharmaceuticals worth $788K as of Q2 2026.
  • Kestra Investment Management sold 5,778 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.74M.
  • Alnylam Pharmaceuticals made up 0.02% of Kestra Investment Management's portfolio in Q2 2026, its #264 holding.
  • Kestra Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Kestra Investment Management's Alnylam Pharmaceuticals position peaked at $2.78M in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Kestra Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.